|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11-06-08
9.7 KB
|
| |
COLUMBIA, Md., Nov 06, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at ...
|
|
Osiris Therapeutics Reports Third Quarter 2008 Financial Results
11-04-08
18.1 KB
|
| |
COLUMBIA, Md., Nov 04, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the third quarter of 2008.
Highlights and Recent Deve...
|
|
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
11-04-08
18.5 KB
|
| |
CAMBRIDGE, Mass. & COLUMBIA, Md., Nov 04, 2008 (BUSINESS WIRE) -- Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to t...
|
|
Osiris Announces Third Quarter 2008 Financial Results Conference Call
10-31-08
12.0 KB
|
| |
COLUMBIA, Md., Oct 31, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leader in stem cell therapeutics, announced today that it will report its financial results for the quarter ended September 30, 2008, on Tuesday, November 4, 2008. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Richard Hunt, Chief Financi...
|
|
Osiris Therapeutics to Present at the 7th Annual BIO Investor Forum
10-27-08
9.7 KB
|
| |
COLUMBIA, Md., Oct 27, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at ...
|
|
Osiris Therapeutics to Present at the JMP Securities Healthcare Focus Conference
10-02-08
9.7 KB
|
| |
COLUMBIA, Md., Oct 02, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Completes Enrollment of Stem Cell Trial to Treat Pulmonary Disease
09-23-08
13.0 KB
|
| |
COLUMBIA, Md., Sep 23, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that it has completed enrollment in a human clinical trial designed to evaluate Prochymal, the Company's proprietary formulation of adult mesenchymal stem cells, for the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD)....
|
|
Osiris Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
09-18-08
9.7 KB
|
| |
COLUMBIA, Md., Sep 18, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics to Present at Thomas Weisel Partners Healthcare Conference
08-28-08
9.7 KB
|
| |
COLUMBIA, Md., Aug 28, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics Reports Second Quarter 2008 Financial Results
08-07-08
20.9 KB
|
| |
COLUMBIA, Md., Aug 07, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leader in stem cell therapeutics, announced today its results for the second quarter of 2008.
Second Quarter Highlights and Recent Developments
-- Completed the technology assets closing under the asset purchase agreement with NuVasive, Inc. for the ...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
